<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Colestipol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Colestipol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Colestipol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11525" href="/d/html/11525.html" rel="external">see "Colestipol: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13064" href="/d/html/13064.html" rel="external">see "Colestipol: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F154485"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Colestid;</li>
<li>Colestid Flavored</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866433"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Colestid</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F154520"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antilipemic Agent, Bile Acid Sequestrant</li></ul></div>
<div class="block doa drugH1Div" id="F154488"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="30d8f8df-d9e0-4987-868a-2e29842e77d1">Primary hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary hypercholesterolemia:</b>
<b>Note:</b> May be considered in patients with fasting triglyceride level ≤300 mg/dL who do not meet cholesterol treatment goals with dietary modification and other lipid lowering therapies (eg, maximally tolerated statin and ezetimibe) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>). <b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Granules: Initial: 5 g once or twice daily; increase by 5 g per day at 1- to 2-month intervals. In patients with preexisting constipation, initiate at 5 g once daily for 5 to 7 days, then increase to 5 g twice daily. Maintenance: 5 to 30 g/day administered once daily or in divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Initial: 2 g once or twice daily; increase by 2 g once or twice daily at 1- to 2-month intervals. Maintenance: 2 to 16 g/day administered once daily or in divided doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="57214e82-9134-4f67-9ba4-de9cd292ccd6">Pruritus with primary biliary cholangitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pruritus with primary biliary cholangitis (off-label use): Oral:</b> Granules: Initial: 5 g once daily; increase as needed, up to 30 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12067457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12067457'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991707"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment is unlikely because not absorbed from the gastrointestinal tract.</p></div>
<div class="block doha drugH1Div" id="F50989028"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment is unlikely because not absorbed from the gastrointestinal tract.</p></div>
<div class="block doe drugH1Div" id="F154489"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52812496"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13064" href="/d/html/13064.html" rel="external">see "Colestipol: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f71eb8fe-d05e-4ef8-91ed-8e7a986cef46">Dyslipidemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dyslipidemia:</b> Limited data available: <b>Note:</b> Bile acid sequestrant therapy should not be used in pediatric patients with hypertriglyceridemia. Statins are recommended as the primary agent for management of hypercholesterolemia, particularly those in high-risk categories. Multivitamin supplementation recommended due to potential folic acid and cholecalciferol malabsorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28437620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28437620'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dosing: Children ≥8 years and Adolescents: Oral: Reported range: 2 to 12 g/day; in one trial, both the 10 g once daily and 5 g twice daily were shown to produce significant lowering of serum cholesterol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12032266','lexi-content-ref-8660081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12032266','lexi-content-ref-8660081'])">Ref</a></span>); doses &lt;10 g suggested to maximize tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28437620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28437620'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed dosing: Children ≥3 years and Adolescents: Very limited data available: 125 to 250 mg/kg/day has been used in patients 3 to 24 years of age (mean age: 13.7 years) with familial hypercholesterolemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7073790']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7073790'])">Ref</a></span>). <b>Note:</b> Although colestipol has been used in patients down to 3 years of age, experts recommend the initiation of drug therapy for management of hypercholesterolemia in pediatric patients who are older (eg ≥10 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28437620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28437620'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729675"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment is unlikely because not absorbed from the gastrointestinal tract.</p></div>
<div class="block dohp drugH1Div" id="F52729676"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment is unlikely because not absorbed from the gastrointestinal tract.</p></div>
<div class="block adr drugH1Div" id="F154461"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Angina, chest pain, peripheral edema, tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Dizziness, fatigue, headache (including migraine and sinus headache), insomnia</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Dermatitis, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal cramps, abdominal pain, anorexia, bloating, constipation, cholecystitis, cholelithiasis, diarrhea, dyspepsia, dysphagia, esophageal obstruction, flatulence, heartburn, hemorrhoidal bleeding, nausea, peptic ulcer, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Arthralgia, arthritis, back pain, myalgia, weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Dyspnea</p></div>
<div class="block coi drugH1Div" id="F154475"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to colestipol or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Complete biliary obstruction; phenylketonurics (Colestid Orange Granules only)</p></div>
<div class="block war drugH1Div" id="F154458"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acidosis: Chronic use may lead to development of hyperchloremic acidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: Chronic use may be associated with bleeding problems due to hypoprothrombinemia from vitamin K deficiency; may be prevented with use of vitamin K therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Constipation: May produce or exacerbate constipation; fecal impaction may occur; initiate therapy at a reduced dose and increase gradually in patients with a history of constipation. Encourage increased fluid and fiber intake; a stool softener may also be indicated. Hemorrhoids may be worsened.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypothyroidism: There is a theoretical risk of developing hypothyroidism, particularly in patients with limited thyroid reserve. Use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertriglyceridemia: Bile acid sequestrants can increase serum triglyceride concentrations. The American College of Cardiology/American Heart Association recommends avoiding use in patients with fasting triglyceride levels ≥300 mg/dL (ACC/AHA [Grundy 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Granules: Colestipol granules should never be taken in dry form; may cause esophageal spasm and/or respiratory distress.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Some products may contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients susceptible to fat-soluble vitamin and folic acid deficiencies: Use with caution in patients susceptible to fat-soluble vitamin deficiencies. Absorption of fat-soluble vitamins A, D, E, and K and folic acid may be decreased; patients should take vitamins ≥4 hours before colestipol.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878397"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">May raise serum triglyceride concentrations; in a trial of combination therapy of colestipol and pravastatin in children and adolescents (&gt;8 years of age), the serum triglycerides increased by 12% from baseline (McCrindle 2002).</p></div>
<div class="block foc drugH1Div" id="F154468"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Granules, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Colestid: 5 g/5 g scoop (300 g, 500 g) [contains aspartame; unflavored flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Colestid Flavored: 5 g/7.5 g scoop (450 g) [contains aspartame; orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 g/5 g scoop (500 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Colestid: 5 g (30 ea [DSC], 90 ea) [unflavored flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Colestid Flavored: 5 g (60 ea) [contains aspartame; orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 g (30 ea, 90 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Colestid: 1 g</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g</p></div>
<div class="block geq drugH1Div" id="F154454"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F154477"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Granules</b> (Colestid Flavored Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g (per gram): $0.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Granules</b> (Colestid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g (per gram): $1.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Granules</b> (Colestipol HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g (per gram): $0.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Colestid Flavored Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g (per each): $9.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Colestid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g (per each): $8.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Colestipol HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g (per each): $3.93</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Colestid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $2.70</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Colestipol HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $1.24 - $1.26</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866434"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Granules, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Colestid: 5 g (5 g) [contains aspartame]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Colestid: 5 g ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Colestid: 1 g</p></div>
<div class="block adm drugH1Div" id="F154472"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Other drugs should be administered at least 1 hour before or 4 hours after colestipol.</p>
<p style="text-indent:-2em;margin-left:2em;">Granules: Do not administer in dry form (to avoid esophageal distress or accidental inhalation). After mixing and administration of granules, rinse glass with a small amount of liquid and ingest to ensure all medication is taken.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Administer tablets 1 at a time, swallowed whole, with plenty of liquid. Do not cut, crush, or chew tablets.</p></div>
<div class="block admp drugH1Div" id="F52612454"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Oral: Other drugs should be administered at least 1 hour before or 4 hours after colestipol.</p>
<p style="text-indent:-2em;margin-left:4em;">Granules: Do not administer in dry form (to avoid GI distress or accidental inhalation). Dry granules should be added to at least 90 mL of liquid and stirred until completely mixed; may be mixed with any beverage or added to soups, cereal, or pulpy fruits (eg, fruit cocktail, crushed pineapple, peaches, pears). After administration, rinse glass with a small amount of liquid to ensure all medication is consumed.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Administer tablets one at a time; swallow whole with plenty of liquid. Do not cut, crush, or chew tablets.</p></div>
<div class="block use drugH1Div" id="F154471"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Primary hypercholesterolemia:</b> Adjunctive therapy to diet in patients with primary hypercholesterolemia</p></div>
<div class="block off-label drugH1Div" id="F25722043"><span class="drugH1">Use: Off-Label: Adult</span><p>Pruritus with primary biliary cholangitis</p></div>
<div class="block mst drugH1Div" id="F7297703"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Colestipol may be confused with calcitriol</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299082"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F154463"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: Bile Acid Sequestrants may decrease the bioavailability of Amiodarone.  Management: Consider alternatives to this combination due to the risk of subtherapeutic amiodarone serum concentrations. If amiodarone is coadministered with colesevelam, administer amiodarone at least 4 hours before colesevelam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Bile Acid Sequestrants may decrease the absorption of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chenodiol: Bile Acid Sequestrants may decrease the serum concentration of Chenodiol.  Management: Administration of chenodiol 5 hours or more after bile acid sequestrants may reduce the magnitude of this interaction.  Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholic Acid: Bile Acid Sequestrants may decrease the absorption of Cholic Acid.  Management: Administer cholic acid at least 1 hour before or 4 to 6 hours after administration of any bile acid-binding products to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Oral): Bile Acid Sequestrants may decrease the absorption of Corticosteroids (Oral). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Bile Acid Sequestrants may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethinyl Estradiol-Containing Products: Bile Acid Sequestrants may decrease the serum concentration of Ethinyl Estradiol-Containing Products.  Management: Administer ethinyl estradiol-containing products 4 hours prior to the administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ezetimibe: Bile Acid Sequestrants may decrease the absorption of Ezetimibe.  Management: Administer ezetimibe at least 2 hours before or 4 hours after any bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fibric Acid Derivatives: Bile Acid Sequestrants may decrease the absorption of Fibric Acid Derivatives.  Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide.  Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: Bile Acid Sequestrants may decrease the absorption of Lomitapide.  Management: Administer lomitapide at least 4 hours before or after administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Bile Acid Sequestrants may decrease the absorption of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maralixibat: Bile Acid Sequestrants may decrease the serum concentration of Maralixibat.  Management: Bile acid sequestrants should be administered either at least 4 hours before, or 4 hours after, maralixibat.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Bile Acid Sequestrants may decrease the absorption of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Fluoride (with ADE).  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, bile acid sequestrants may impair the absorption of fat-soluble vitamins.  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron).  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Bile Acid Sequestrants may decrease the serum concentration of Mycophenolate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Niacin: Bile Acid Sequestrants may decrease the absorption of Niacin.  Management: Consider separating the administration times of niacin and bile acid sequestrants by a few hours in order to reduce the potential for decreased efficacy of these agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Bile Acid Sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obeticholic Acid: Bile Acid Sequestrants may decrease the serum concentration of Obeticholic Acid.  Management: Administer obeticholic acid at least 4 hours before or at least 4 hours after the administration of bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Odevixibat: Bile Acid Sequestrants may decrease the serum concentration of Odevixibat.  Management: Bile acid sequestrants should be administered either at least 4 hours before, or 4 hours after, odevixibat.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pravastatin: Bile Acid Sequestrants may decrease the serum concentration of Pravastatin.  Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: Bile Acid Sequestrants may decrease the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raloxifene: Bile Acid Sequestrants may decrease the absorption of Raloxifene.  Management: Consider separating the doses of raloxifene and bile acid sequestrants by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: Bile Acid Sequestrants may decrease the absorption of Taurursodiol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: Bile Acid Sequestrants may decrease the serum concentration of Teriflunomide.  Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is unlikely to be effective at avoiding the interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Bile Acid Sequestrants may decrease the absorption of Tetracyclines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Bile Acid Sequestrants may decrease the absorption of Thiazide and Thiazide-Like Diuretics. The diuretic response is likewise decreased.  Management: Consider separating administraton of bile acid sequestrants and thiazide diuretics by at least 4 hours. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Bile Acid Sequestrants may decrease the serum concentration of Thyroid Products.  Management: Administer oral thyroid products at least 4 hours prior to or one hour after bile acid sequestrants, or monitor for decreased serum concentrations and clinical effects of oral thyroid products during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ursodiol: Bile Acid Sequestrants may decrease the serum concentration of Ursodiol.  Management: Administer ursodiol 1 hour before or at least 4 to 5 hours after bile acid sequestrants to minimize the potential for any significant interaction. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: Bile Acid Sequestrants may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs.  Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F13277388"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Lipid concentrations increase during pregnancy as required for normal fetal development. When increases are greater than expected, supervised dietary intervention should be initiated. Bile acid sequestrants are recommended when treatment is needed (Avis 2009; Jacobson 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Colestipol is not absorbed systemically (&lt;0.17%), but may interfere with maternal vitamin absorption; therefore, regular prenatal supplementation may not be adequate.</p></div>
<div class="block brc drugH1Div" id="F13277389"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Due to lack of systemic absorption (&lt;0.17%), colestipol is not expected to be present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">When treatment for hypercholesterolemia in breastfeeding women is needed, therapy with bile acid sequestrants may be considered (Jacobson 2015; NICE 2008). However, because use may interfere with maternal vitamin absorption, the manufacturer recommends caution be used if administered to breastfeeding women.</p></div>
<div class="block dic drugH1Div" id="F154478"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine.</p></div>
<div class="block mop drugH1Div" id="F13389617"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Lipid profile (fasting or nonfasting) before initiating treatment. Fasting lipid profile should be rechecked 4 to 12 weeks after starting therapy and every 3 to 12 months thereafter (AHA/ACC [Grundy 2018])</p></div>
<div class="block pha drugH1Div" id="F154457"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds with bile acids to form an insoluble complex that is eliminated in feces; it thereby increases the fecal loss of bile acid-bound low density lipoprotein cholesterol</p></div>
<div class="block phk drugH1Div" id="F154474"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Lowering of serum cholesterol: ~1 month; LDL-C reduction: ~19%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: None </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F154479"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Colestid | Colestid orange</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cholestabyl | Colestid</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Colestid | Lestid</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lestid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Colestid | Lestid</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lestid</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Colestid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19741526">
<a name="19741526"></a>Avis HJ, Hutten BA, Twickler MT, et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? <i>Curr Opin Lipidol</i>. 2009;20(6):484-490. doi: 10.1097/MOL.0b013e3283319127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/19741526/pubmed" id="19741526" target="_blank">19741526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colestid.1">
<a name="Colestid.1"></a>Colestid, Flavored Colestid (colestipol hydrochloride) [prescribing information]. New York, NY: Pfizer; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colestid.2">
<a name="Colestid.2"></a>Colestid granules (colestipol hydrochloride) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Company; May 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colestid.3">
<a name="Colestid.3"></a>Colestid granules (colestipol hydrochloride) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colestid.4">
<a name="Colestid.4"></a>Colestid orange granules (colestipol hydrochloride) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colestid.5">
<a name="Colestid.5"></a>Colestid tablets (colestipol hydrochloride) [prescribing information]. New York, NY: Pfizer; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colestid.6">
<a name="Colestid.6"></a>Colestid tablets (colestipol hydrochloride) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14025214">
<a name="14025214"></a>Datta DV, Sherlock S. Treatment of pruritus of obstructive jaundice with cholestyramine. <i>B Med J.</i> 1963;1(5325):216-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/14025214/pubmed" id="14025214" target="_blank">14025214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation. </i>2012;126(25):3097-3137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586774">
<a name="30586774"></a>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol [published online November 10, 2018]. <i>Circulation</i>. 2018. doi: 10.1161/CIR.0000000000000625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/30586774/pubmed" id="30586774" target="_blank">30586774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26699442">
<a name="26699442"></a>Jacobson TA, Maki KC, Orringer CE, et al; NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2 [published correction appears in <i>J Clin Lipidol</i>. 2016;10(1):211]. <i>J Clin Lipidol</i>. 2015;9(6 suppl):s1-122.e1. doi: 10.1016/j.jacl.2015.09.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/26699442/pubmed" id="26699442" target="_blank">26699442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28437620">
<a name="28437620"></a>Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/28437620/pubmed" id="28437620" target="_blank">28437620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30070375">
<a name="30070375"></a>Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2019;69(1):394-419. doi: 10.1002/hep.30145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/30070375/pubmed" id="30070375" target="_blank">30070375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12032266">
<a name="12032266"></a>McCrindle BW, Helden E, Cullen-Dean G, et al, "A Randomized Crossover Trial of Combination Pharmacologic Therapy in Children With Familial Hyperlipidemia," <i>Pediatr Res</i>, 2002, 51(6):715-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/12032266/pubmed" id="12032266" target="_blank">12032266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17377073">
<a name="17377073"></a>McCrindle BW, Urbina EM, Dennison BA, et al, "Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing," <i>Circulation</i>, 2007, 115(14):1948-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/17377073/pubmed" id="17377073" target="_blank">17377073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16971976">
<a name="16971976"></a>McPherson R, Frohlich J, Fodor G, et al. Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease [published correction appears in <i>Can J Cardiol</i>. 2006, 22(12):1077]. <i>Can J Cardiol</i>. 2006;22(11):913-927.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/16971976/pubmed" id="16971976" target="_blank">16971976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.1">
<a name="NHLBI.1"></a>National Heart, Lung, and Blood Institute, "Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents," Clinical Practice Guidelines, 2011, National Institutes of Health. Available at <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf%20" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf </a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: NICE. (Clinical Guideline 71). Available at: www.nice.org.uk/CG71. Published August 2008. Updated November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21739227">
<a name="21739227"></a>Scaldaferri F, Pizzoferrato M, Ponziani FR, et al. Use and Indications of Cholestyramine and Bile Acid Sequestrants. <i>Intern Emerg Med.</i> 2011 [pub ahead of print].<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/21739227/pubmed" id="21739227" target="_blank">21739227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12067457">
<a name="12067457"></a>Schlichting J, Leuschner U. Drug therapy of primary biliary diseases: classical and modern strategies. <i>J Cell Mol Med</i>. 2001;5(1):98-115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/12067457/pubmed" id="12067457" target="_blank">12067457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7073790">
<a name="7073790"></a>Schlierf G, Mrozik K, Heuck CC, et al. "Low dose" colestipol in children, adolescents and young adults with familial hypercholesterolemia. <i>Atherosclerosis</i>. 1982;41(1):133-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/7073790/pubmed" id="7073790" target="_blank">7073790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24222016">
<a name="24222016"></a>Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(25 Suppl 2):S1-45. doi:10.1161/01.cir.0000437738.63853.7a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/24222016/pubmed" id="24222016" target="_blank">24222016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8660081">
<a name="8660081"></a>Tonstad S, Sivertsen M, Aksnes L, Ose L. Low dose colestipol in adolescents with familial hypercholesterolaemia. <i>Arch Dis Child</i>. 1996;74(2):157-160. doi:10.1136/adc.74.2.157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/colestipol-drug-information/abstract-text/8660081/pubmed" id="8660081" target="_blank">8660081</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9294 Version 255.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
